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Aberrant promoter hypermethylation or histone modifications are recognized as
an important mechanism in cancer initiation and progression.
1 These epigenetic
mechanisms are recognized as a “third pathway” in Knudson’s model of tumor-
suppressor gene inactivation and can affect gene expression without accom-
panying genetic changes.
2 DNA methylation occurs in the cytosine-guanine
sequence (CpG) in mammalian DNA strands. The pattern of methylation at
cytosine residues in the CpG sequences is established during early development
and is heritable.
3 In humans, approximately 70% of CpG dinucleotides are
methylated. The frequency of the CpG dinucleotide is relatively low in most of
the human genome because of CG suppression. However, genomic sequencing
reveals that CpG sites are unevenly distributed in the mammalian genome. About
60% of genes have 5’ promoter regions located in the CpG rich 0.3-2 kb stretches
of DNA called CpG islands. CpG islands are normally unmethylated.
4,5 Promoter
associated CpG islands need to be protected against DNA hypermethylation that
results in irreversible inhibition of gene expression. In normal cells, this is evidenced
by methylation associated silencing of imprinted genes and inactive X chromo-
some genes. In cancers, this mechanism is utilized to inactivate tumor-suppressor
genes.
6
Histone modification is another key mechanism in transcriptional regulation,
which is well conserved through a variety of species.
7-9 The less structured N-
terminal domains of all core histones protrude from the core histone and are subject
to chemical modifications, such as acetylation, methylation, and phosphorylation
at certain residues.
10,11 The modification patterns of histone have been linked to
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DNA methylation, histone modifications, and the chromatin structure are profoundly altered in human cancers. The
silencing of cancer-related genes by these epigenetic regulators is recognized as a key mechanism in tumor
formation. Recent findings revealed that DNA methylation and histone modifications appear to be linked to each
other. However, it is not clearly understood how the formation of histone modifications may affect DNA
methylation and which genes are relevantly involved with tumor formation. The presence of histone modifications
does not always link to DNA methylation in human cancers, which suggests that another factor is required to
connect these two epigenetic mechanisms. In this review, examples of studies that demonstrated the relationship
between histone modifications and DNA methylation in human cancers are presented and the potential implications
of these epigenetic mechanisms in human neoplasia are discussed.
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INTRODUCTIONbiological function and act as a “histone code”, which
implies that transcription states can be predicted by simply
deciphering this code.
8 Recent studies showed that histone
modifications co-operate with DNA methylation to affect
gene inactivation in some tumor suppressor genes.
12-16 DNA
methylation and histone modifications might interact with
each other and establish stable gene silencing. In addition
to this interaction, histone H3 lysine 27 trimethylation
(H3K27me3), which is involved in the regulation of home-
otic (Hox) gene expression and in the early steps of X-
chromosome inactivation in women, can be solid silencing
machinery that is independent of DNA methylation in
human cancers.
17-19
Although evidence for aberrant DNA methylation and
histone modification changes in cancers is accumulating,
how aberrant DNA methylation and histone modifications
interact in a certain loci, why some genes are particular
targets of epigenetic machinery, and whether aberrant
DNA methylation and histone modifications confer specific
roles in cancer initiation and progression remains unclear.
In this review, we discuss the current understanding of
gene silencing by DNA methylation and histone modifica-
tions, focusing especially on histone H3 lysine 9 methyla-
tion (H3K9me) and H3K27me3, as related to human
cancers. 
Histone modifications
Nucleosomes consist of 147 bp DNA wrapped around the
core histone that comprises histone proteins, H2A, H2B,
H3, and H4 (Fig. 1A).
7,20 The N-terminal domains of all
core histones are subject to chemical modifications, such
as acetylation, methylation, ubiquitylation, and phosphory-
lation at certain residues.
8 Histone modifying enzymes
bring the complexity of post-translational modifications
that can either activate or repress transcription, depending
on the type of chemical modification and its location in the
histone protein. The modification pattern of histone has
been linked to chromatin structure and gene function
during development as well as tumorigenesis.
6,10,11
These different combinations of histone tail modifica-
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Fig. 1.Schematic of histone modifications and modifiers.  (A) DNA is compacted in the nucleus. The fundamental repeating unit of chromatin is the nucleosome, which
consists of 147 base pairs of DNA wrapped around an octamer of the following core histone proteins: H2A, H2B, H3, and H4. Histone proteins consist of less structured
amino-terminal tails (tail domain) that protrude from the nucleosome and globular carboxy-terminal domains make up the nucleosome scaffold (fold domain). The
histone tail domain could be a target of a variety of post-translational modifications, including acetylation (Ac), methylation (Me) and ubiquitination of lysine (K)
residues, phosphorylation (P) of serine (S) and threonine (T) residues, and methylation of arginine (R) residues. (B) Lysine residues in the histone H3 tail are the targets
of methyltransferases and demethylases. Histone methylase, MLL, myeloid/lymphoid or mixed-lineage leukemia; SMYD3, SET and MYND domain containing 3; RIZ1,
retinoblastoma protein-interacting zinc-finger protein 1; EZH2, enhancer of zeste homologue 2; NSD1, Nuclear receptor binding SET domain protein 1. Histone
demethylases, LSD1, lysine-specific histone demethylase 1; SMCX, Smcx homolog, X chromosome; SMCY, Smcy homolog, Y chromosome.
42
A
Btions influence transcription by affecting chromatin struc-
tures.
8 Modifications on the lateral surface of the core
histone could also affect histone-DNA interactions as well
as N-terminal domains. The respective enzymes vary in
their potential to induce mono-, di-, or tri-methylation (Fig.
1B). Since lysine methylation is more stable than other
modifications, there has been until recently, discussion as
to why stably methylated histone lysine residues contri-
buted to the establishment and propagation of different
patterns of gene expression in the same genome.
21 Recent
comprehensive reports revealed that histone methylation is
reversible by demethylases (Fig. 1B). Given that histone
methylation has important roles in development and other
biological events, including tumorigenesis, histone deme-
thylases might be key molecules in cellular processes.  
Generally, acetylation of lysine residues on histone H3
and H4 leads to the formation of an open chromatin struc-
ture, which indicates transcriptional activity.
22 In contrast,
methylation on lysine residues link to either activation or
repression depending on its location.
11 Trimethylation at
K9 on histone H3 (H3K9me3) or K20 on histone H4
(H4K20me3) has been shown to form heterochromatin
from yeast to humans. Dimethylation at K9 (H3K9me2) is
associated with inactivation of gene expression at the
euchromatic region. Trimethylation at histone H3K27
(H3K27me3) is a distinct histone modification involved in
the regulation of homeotic (Hox) gene expression and in
the early steps of X-chromosome inactivation in women.
23
This process is mechanistically linked to polycomb group
(PcG) proteins. PcG proteins, an enhancer of zeste 2
(EZH2), which is a member of polycomb repressor complex
2 (PRC2), has histone methyltransferase activity with
substrate specificity for H3K27. H3K27me3 serves as a
signal for specific binding of the chromodomain of another
polycomb repressor complex, PRC1, which includes B
lymphoma Mo-MLV insertion region 1 (BMI-1), ring
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Fig. 2. Bivalent histone modification in ES cells resolve during differentiation. In embryonic stem cell  (ES cells), active mark histoneH3 lysine 4 di-methylation / tri-
methylation (H3K4me2/3) and repressive mark histoneH3 lysine 27 trimethylation (H3K27me3) coexisted (bivalent modification status) on development-related genes,
which might be necessary for sustaining an undifferentiated state. The bivalent modifications in their promoter regions resolved during ES cell differentiation into either
H3K27me3 or H3K4me3 domains.finger protein 1 (RING1), human polycomb (HPC), and
human polyhomeotic homologue (HPH).
24 The binding of
PRC1 blocks the recruitment of transcriptional activation
factors, such as SWI/SNF, and the presence of PRC1
prevents initiation of transcription by RNA polymerase
II.
25,26 Di- or tri-methylation on K4 on histone H3
(H3K4me2/me3) localizes to sites of active transcription
and this modification may be stimulatory for transcription.
Several recent studies indicated the existence of ‘bivalent’
domains consisting of dual marks of repressive histone
H3K27me3 and the activation of histone H3K4me3
modifications on development-associated genes that are
silent in ES cells and activated during differentiation (Fig.
2).
27,28 The dynamic alteration of lysine methylation
contributes to reversible and plastic regulation of gene
expression in varieties of the cellular process, which
contrasts with stable gene inactivation by DNA
methylation.
DNA methylation in cancer
Promoter DNA methylation is the most widely studied
epigenetic modification of human cancers.
29 Compared to
normal tissues, cancer DNA shows global hypomethylation
and hypermethylation at gene-associated CpG islands that
are normally unmethylated. Cancer hypomethylation is
found in repetitive elements localized in satellite sequences
or pericentromeric regions and has been reported to lead to
genomic instability.
30 Hypermethylation in CpG islands is
found in several types of cancers and recognized as a
mechanism of tumor suppressor gene silencing. Initial
studies indicated DNA methylation as a cause of tumori-
genesis. For example, inactivation of the cyclin-dependent
kinase inhibitor P16/CDKN2A by methylation leads to the
disruption of cell-cycle regulation and potentially provides
a growth advantage to affected cells.
31 Another tumor
suppressor genes, P14/ARF is also a target of inactivation
by DNA methylation.
32 P14/ARF activates P53 through
interactions with MDM2, and losses of P14/ARF negati-
vely affect P53 function. Inactivation by methylation has
also been found in DNA repair genes, such as hMLH1 and
MGMT.
33,34 Tumor suppressor gene silencing by DNA
methylation promotes cell proliferation and may provide
strong selective advantages. However, potential onco-
genes, such as COX2 and hTERT, are also targets of
aberrant DNA methylation, which illustrates the point that
methylation is initially independent of gene function.
35,36
These data suggest that cancer-associated DNA methy-
lation is not restricted to tumor suppressor genes and that
the profile of methylation in cancers may not simply be a
result of selection.  
Recent accumulating evidence suggests that DNA methy-
lation is a late step in the gene silencing process, even
though such methylation has been detected in pre-cancerous
tissues. The establishment of fundamental DNA methy-
lation patterns during early development might be accomp-
lished through histone modification.
37 H3K4me has recently
been suggested to protect gene promoters from de novo
DNA methylation in somatic cells.
38,39 Therefore, de novo
methylation is closely associated with the removal of
methylation from H3K4 by Lsd1 and jmj-C containing
demethylases [Jarid 1a and Jarid 1b, also known as K
(lysine)-demethylases 5A (KDM5A) and K (lysine)-
demethylases 5B (KDM5B)] on certain loci.
40-42 After
removal of methylation from H3K4, Dnmt3A/Dnmt3B-
Dnmt3L complexes can target these loci, resulting in de
novo methylation.
37,43 However, H3K4me marks most CpG
islands, since RNA polymerase II recruits specific H3K4
methyltransferases, which link to CpG islands of actively
transcribed genes.
39,44 Contact between DNMT3L and
nucleosomes are inhibited by H3K4me. As a result, most
CpG is prevented from de novo methylation. 
The DNA methylation pattern is maintained by DNA
methyltransferase 1 (Dnmt1), which is associated with a
replication complex. Studies have indicated that Dnmt1,
together with UHRF1 (also known as Np95 or ICBP90),
recognizes the hemimethylated CpG residues and
methylates the opposite strand, resulting in a faithful copy
of the methylation profile of the parent cell.
45 Regulation of
Dnmt1 methylation by histone demethylase Lsd1 and
histone methylase Set7/9 has recently been reported.
46
According to this model, Lsd1counteracts methylation of
Dnmt1 by Set7/9, which results in the stabilization of
Dnmt1 and enables DNA methylation to be maintained.  
Once DNA methylation has been established on CpG
islands, this modification is generally irreversible without
artificially altering key factors in the cells, as was shown in
iPS cells.
47,48 Therefore, facultative regulation by histone
modifications is stably determined by DNA methylation
on the silenced loci in cancer cells. 
Interrelation between DNA methylation and histone
modifications
Early studies have shown that the link between DNA
methylation and histone modifications is mediated by a
group of proteins with methyl DNA binding activity,
including methyl CpG binding protein 2 (MeCP2), Methyl-
CpG binding domain protein 1 (MBD1), and Kaiso [also
known as ZBTB 33 (Zinc finger and BTB domaincon-
taining protein 33)]. These proteins localize to DNA
methylated promoters and recruit a protein complex that
contains histone deacetylases (HDACs) and histone
methyltransferases.
49-51 These studies suggest DNA methy-
lation induce chromatin structural changes through alteration
of histone modifications. It is known that DNA methy-
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methylation affects histone modifications.
38,39  However,
early studies in fungi (Neurospora crassa) show that
mutations of histone H3K9 methyltransferase reduced
DNA methylation, indicating a simple linear model in
which H3K9 methylation acts as an upstream epigenetic
mark that signals to DNA methylation.
52 In embryonic stem
cells, Oct3/4 is inactivated after lineage commitment. For
this silencing process, a repressor complex is recruited that
contains histone methyltransferase G9a and enzymes with
histone deacetylase activity. Subsequently, methyltrans-
ferase, DNMT3A, and DNMT3b, which catalyze de novo
DNA methylation, are recruited at the promoter.
13 Intri-
guingly, interaction between G9a and the DNMTs depends
on the ankyrin motif of G9a.
53 By contrast, the SET domain,
which is responsible for the methyltransferase activity of
G9a, does not interact with DNMTs. Indeed, mutation of
the SET domain is inert in methyltransferase activity and
disrupts H3K9 methylation without affecting DNA methy-
lation.
54,55 These data suggest that DNA methylation on the
promoter depends on the recruitment of G9a (especially
ankyrin motif), rather than the histone methyltransferase
activity itself. The interactions between DNA methylation
and histone H3K9 methylation currently fit a model
whereby these two changes form a reinforcing silencing
loop or bidirectional crosstalk, and this may explain why
silencing is less stable in organisms that lack DNA methy-
lation (Fig. 3).
2
Recently, links between PcG-mediated methylation on
H3K27 and de novo DNA methylation in cancers were
described using ChIP analyses coupled with bioinformatic
database mining, which supports the conventional view
that the mark imposed by PRC2 during development may
predispose some genes for later de novo methylation (Fig.
3).
14-16 Genome-wide analysis combined with methylation
prediction models revealed that CpG islands predicted to
be methylation-prone revealed a strong association with
embryonic targets of PRC2 and a subset of PRC2 targets
that were more likely to be hypermethylated in cancer.
56
Biochemical study also showed that DNMTs bind to
EZH2, however, this interaction seems to be detected only
under certain conditions.
48,57,58 Obviously, the presence of
histone methylation at H3K9 or H3K27 does not always
lead to de novo methylation. Indeed, subsets of PcG target
genes are methylated in one cancer, even though these
same genes are completely unmethylated in another cancer
from the same normal tissue origins. Additional factors are
required for triggering DNA methylation in the genes
enriched with those histone modifications.   
More recently, comprehensive genome-wide and func-
tional analysis revealed that PcG-mediated H3K27me3 is a
mechanism of tumor-suppressor gene silencing in cancer
that is potentially independent of promoter DNA methy-
lation and a direct interaction between PcG-mediated
Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers
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Fig. 3. Two distinct histone modifications for gene silencing in human cancers. In cancer cells, interactions between DNA methylation and histone H3K9 methylation
have been observed, which may contribute to forming and reinforcing a silencing loop leading to stable silencing machinery. A polycomb group (PcG) protein,
enhancer of zeste 2 (EZH2), which is a member of the polycomb repressor complex 2 (PRC2), has a histone methyltransferase activity with substrate specificity for
H3K27. H3K27triM serves as a signal for specific binding of the chromodomain of another polycomb repressor complex, PRC1. Binding of PRC1 blocks the recruitment
of transcriptional activation factors, and the presence of PRC1 prevents initiation of transcription.methylation on H3K27 and de novo DNA methylation
pathways is unlikely in cancers.
18,19 This independence of
DNA-methylation and histone marking appear to conflict
with previous studies. It must be noted that the majority of
genes enriched with repressive mark H3K27me3 in prostate
cancers do not have the CpG island in the promoter regions,
whereas genes targeted by PcG complexes are generally
associated with CpG island promoters in ES cells.
18,48  This
indicates that targets of PcG-mediated methylation on
H3K27 among ES cells, normal tissue cells, and cancer cells
are different and that cancer cells usurp the silencing mecha-
nisms to extinguish functional pathways by H3K27me3.
Now, three lines might be considered in the silencing
machinery associated with PcG-mediated methylation on
H3K27 (Fig. 4). First, genes are de novo repressed by
PcG-mediated methylation on H3K27, which supports the
observation of distinct target genes between normal and
cancer cells (particularly targeting non-CpG island promo-
ters). Second, during early tumorigenesis, subsets of genes
become methylated, and a large portion of these are
initially marked by the PcG complex (targeting CpG island
promoters).  In this case, several genes undergo epigenetic
programming, in which genes that are originally silenced
by PcG acquire DNA methylation as an alternative silencing
mechanism. This epigenetic switch to DNA methylation-
mediated repression reduces the epigenetic plasticity,
locking the silencing of key regulators and contributing to
tumorigenesis.
19 Third, genes that are originally silenced by
PcG acquire DNA methylation to some extent. In this case,
H3K27me3 and DNA methylation co-exist on the same
promoter and PcG-mediated H3K27me3 is the dominant
silencing machinery, which can be reactivated by inhibition
of PRC complexes. In cancers it appears that different
forms of gene silencing contribute to tumorigenesis, which
range from a flexible and plastic repressor-based mechanism
to a highly stable inactivation that is maintained by DNA
methylation.
Future direction:  perspectives on epigenetic therapy
This review has focused on the relationship between two
major epigenetic mechanisms: DNA methylation and
histone methylation. Clarifying this relationship is impor-
tant in the context of cancer epigenetic therapy. Restoring
gene function silenced by epigenetic changes in cancer has
the potential of ‘normalizing’ cancer cells by epigenetic
therapy. This could have a serious impact on the prevention
and treatment of human cancers. However, there are
important questions that must be understood in regard to
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Fig. 4. Model of de novo DNA methylation and de novo histone modifications in human cancers. The bivalent modifications in ES cells were resolved during
differentiation into H3K4me3 domains when genes are actively transcribed. Exposure to chronic inflammation or a carcinogen leads to an imbalanced histone
modification that is not normally observed. Subsequently, as part of an aberrant regulatory program in cancer, de novo H3K27me3 occupies the promoter regions,
which are not occupied by PcG protein in ES cells (major target genes have non-CpG promoters). In this situation, the two epigenetic mechanisms, PRC and DNA
methylation, do not overlap each other. A subset of promoters (CpG promoters), which are initially marked by the PcG complex in ES cells, become DNA
hypermethylated. PRC marks are reduced during or after the establishment of DNA hypermethylation. This epigenetic switch to DNA methylation-mediated repression
reduces epigenetic plasticity, locks the silencing of key regulators and contributes to tumorigenesis. In some genes, H3K27me3 and DNA methylation co-exist on the
same promoter and PcG-mediated H3K27me3 appears to be the dominant silencing machinery.  human cancers and how DNA methylation affects chro-
matin structure and vice versa remain. It will be important
to elucidate the precise role of these epigenetic mechanisms
that allow cancer cells to revert to a more normal state
through epigenetic reprogramming.  
HDAC inhibitors lead to the accumulation of acetylation
in histones, which results in reversion of chromatin status
and transcriptional activity to a normal state.
59 HDAC inhi-
bitors have been shown to induce P21, which is responsible
for cell cycle arrest and cell differentiation. Another
possible role of HDAC inhibitors in antitumor activity
might be to inhibit PcG proteins, some of which have been
recognized as important and uniquely acting oncogenic
proteins, in cancers. Since PcG-mediated gene silencing is
initiated by the HDAC activity of PRC2, inhibition of
HDAC can efficiently reactivate the H3K27me3 target
genes.
18,60
DNA methylation is a therapeutic target of human
cancers.
59,61 The cytosine analogues, 5-azacytidine and 5-
aza-2’-deoxycytidine, are powerful inhibitors of DNA
methylation, which are incorporated into DNA during cell
division. They trap DNA methyltransferases and lead to
cell differentiation and growth repression. These demethy-
lating agents have received FDA approval for the treatment
of myelodysplastic syndrome. However, transiently induced
demethylation is impaired after the withdrawal of chemicals,
which has been suggested in cell line studies.
62 This pheno-
menon might be partially explained by epigenetic memory
retained in chromatin, which may include histone methyla-
tion and interfere with the complete epigenetic reprogram-
ming in cancer cells, as shown in this review. Combining
DNA methyltransferase and histone methyltransferase
inhibitors might provide a clue to solving this incomplete
reprogramming. In addition, the synergistic effects between
DNA methyltransferase and HDAC inhibitors suggest
clinical trials of this approach to restore gene function
silenced by aberrant chromatin changes in cancers.
63
Nevertheless, complete understanding of these epigenetic
modifications and their cross-talk will lead to the develop-
ment of the most effective therapies possible. With such
knowledge of epigenetics at our disposal, we may yield the
full capacity to not only treat but to prevent cancer. By
correcting epigenetic abnormalities that predispose to
cancers, the promise for epigenetic therapies as an essential
treatment option will be achieved.
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